Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.64 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253028 | 0.87 | SMO (0.81) | SMOCNR2ALDH1A1HPGDKMT2A | |
| SCHEMBL4257905 | 0.84 | SMO (0.67) | SMOCNR2NPC1RAB9AKMT2A | |
| SCHEMBL4263804 | 0.82 | SMO (0.74) | SMOCNR2ALDH1A1HPGDKMT2A | |
| SCHEMBL12170948 | 0.82 | NPC1 (0.66) | SMOCNR2NPC1RAB9ATSHR | |
| SCHEMBL4257047 | 0.81 | SMO (0.66) | SMONPC1RAB9AALDH1A1HPGD | |
| SCHEMBL4262816 | 0.81 | NPC1 (0.62) | SMONPC1RAB9AALDH1A1KCNK3 | |
| SCHEMBL4254933 | 0.81 | SMO (0.79) | SMONPC1RAB9AKMT2AMAPT | |
| SCHEMBL4257702 | 0.80 | SMO (0.60) | SMONPC1RAB9AADORA1ALDH1A1 | |
| SCHEMBL16592480 | 0.78 | ADORA1 (0.73) | NPC1RAB9AADORA1ADORA2AALDH1A1 | |
| SCHEMBL4255817 | 0.78 | SMO (1.00) | SMOALDH1A1HPGDKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | claimed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | SMO 1063/4885CNR2 805/4885NPC1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.